Antifracture efficacy of currently available therapies for postmenopausal osteoporosis

Drugs

Volumn 71, Issue 1, 2011, Pages 65-78

  Reginster, Jean Yves ^a  

^a Policliniques L BRULL Quai Godefroid Kurth   (Belgium)

Author keywords

[No Author keywords available]

Indexed keywords

ALENDRONIC ACID; BAZEDOXIFENE; DENOSUMAB; IBANDRONIC ACID; LASOFOXIFENE; PARATHYROID HORMONE[1-34]; PLACEBO; RALOXIFENE; RISEDRONIC ACID; STRONTIUM RANELATE; ZOLEDRONIC ACID;

BONE DENSITY; CLINICAL DECISION MAKING; DRUG DOSE INCREASE; DRUG EFFICACY; DRUG INTERMITTENT THERAPY; DRUG MECHANISM; DRUG SAFETY; DRUG WITHDRAWAL; FRAGILITY FRACTURE; HIP FRACTURE; HUMAN; OUTCOME ASSESSMENT; POSTMENOPAUSE OSTEOPOROSIS; REVIEW; RISK FACTOR; TREATMENT INDICATION; VERTEBRA FRACTURE;

BONE DENSITY; BONE DENSITY CONSERVATION AGENTS; CLINICAL TRIALS, PHASE III AS TOPIC; DIPHOSPHONATES; FEMALE; FRACTURES, BONE; HUMANS; OSTEOPOROSIS, POSTMENOPAUSAL; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SELECTIVE ESTROGEN RECEPTOR MODULATORS; TREATMENT OUTCOME;

EID: 78650822592     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11587570-000000000-00000     Document Type: Review

References (63)

1. Kanis J, Burlet N, Cooper C, et al. European Guidance for the diagnosis and treatment of osteoporosis in postmeno-pausal women. Osteoporos Int 2008 Apr; 19 (4): 399-428.
2. Reginster J-Y, Rizzoli R. Innovation in skeletal medicine. In: Reginster J-Y, Rizzoli R, editors. Innovation in skeletal medicine. Issy-les-Moulineaux: Elsevier, 2007: 7-9.
3. Kanis JA, on behalf of the World Health Organization Scientific Group. Assessment of osteoporosis at the primary healthcare level. Technical report. Sheffield: WHO Centre for Metabolic Bone Diseases, 2007: 38.
4. Nevitt MC, Ettinger B, Black DM, et al. The association of radiographically detected vertebral fracture with back pain and function: a prospective study. Ann Intern Med 1998 May; 128 (10): 793-800.
5. Sambrook P, Cooper C. Osteoporosis. Lancet 2006 Jun; 367 (9527): 2010-8.
6. Lindsay R, Silverman SL, Cooper C, et al. Risk of new vertebral fracture in the year following a fracture. JAMA 2001 Jan; 285 (3): 320-3.
7. Center JR, Bliuc D, Nguyen TV, et al. Risk of subsequent fracture after low-trauma fracture in men and women. JAMA 2007 Jan; 297 (4): 387-94.
8. Kanis JA, Johnell O, De Laet C, et al. A meta-analysis of previous fracture and subsequent fracture risk. Bone 2004 Aug; 35 (2): 375-82.
9. Cooper C, Campion G, Melton 3rd LJ. Hip fractures in the elderly: a world-wide projection. Osteoporos Int 1992 Nov; 2 (6): 285-9.
10. Rizzoli R, Bruyere O, Cannata-Andia JB, et al. Manage-ment of osteoporosis in the elderly. Curr Med Res Opin 2009 Oct; 25 (10): 2373-87.
11. Boonen S, Singer AJ. Osteoporosis management: impact of fracture type on cost and quality of life in patients at risk for fracture. Curr Med Res Opin 2008 Jun; 24 (6): 1781-8.
12. Ioannidis G, Papaioannou A, Hopman WM, et al. Relation between fractures and mortality: results from the Canadian Multicentre Osteoporosis Study. CMAJ 2009 Sep; 181 (5): 265-71.
13. Cauley J, Thompson DE, Ensrud KC, et al. Risk of mor-tality following clinical fractures. Osteoporos Int 2000; 11 (7): 556-61.
14. Leibson CL, Tosteson AN, Gabriel SE, et al. Mortality, disability, and nursing home use for persons with and without hip fracture: a population-based study. J Am Geriatr Soc 2002 Oct; 50 (10): 1644-50.
15. Richmond J, Aharonoff GB, Zuckerman JD, et al. Mortality risk after hip fracture.JOrthop Trauma 2003 Jan;17 (1): 53-6.
16. Empana JP, Dargent-Molina P, Breart G. Effect of hip fracture on mortality in elderly women: the EPIDOS prospective study. J Am Geriatr 2004 May; 52 (5): 685-90.
17. Abrahamsen B, van Staa T, Ariely R, et al. Excess mortality following hip fracture: a systematic epidemiological review. Osteoporos Int 2009 Oct; 20 (10): 1633-50.
18. Salkeld G, Cameron ID, Cumming RG, et al. Quality of life related to fear of falling and hip fracture in older women: a time trade off study. BMJ 2000 Feb; 320 (7231): 341-6.
19. Rabenda V, Manette C, Lemmens R, et al. The direct and indirect costs of the chronic management of osteoporosis: a prospective follow-up of 3440 active subjects. Osteoporos Int 2006; 17 (9): 1346-52.
20. International Osteoporosis Foundation. Osteoporosis in the European Community: a call to action. An audit of policy developments since 1998 [online]. Available from URL: http://www.iofbonehealth.org/download/osteofound/ file manager/publications/pdf/eu-report-2001.pdf [Accessed 2010 Sep 1].
21. Reginster JY, Burlet N. Osteoporosis: a still increasing pre-valence. Bone 2006 Feb; 38 (2 Suppl. 1): S4-9.
22. International Osteoporosis Foundation. Osteoporosis in the European Union in 2008: ten years of progress and ongoing challenges [online]. Available from URL: http://www.sante. public.lu/publications/maladies-traitements/osteoporose/ osteoporosis-eu-2008/osteoporosis-eu-2008.pdf [Accessed 2010 Sep 1].
23. Body JJ, Bergmann P, Boonen S, et al. Evidence-based guidelines for the pharmacological treatment of postmen-opausal osteoporosis: a consensus document by the Belgian Bone Club. Osteoporos Int 2010 Oct; 21 (10): 1657-80.
24. Drake MT, Clarke BL, Khosla S. Bisphosphonates: me-chanism of action and role in clinical practice. Mayo Clin Proc 2008 Sep; 83 (9): 1032-45.
25. Delmas PD. Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases. J Clin Densitom 2008 Apr-Jun; 11 (2): 325-38.
26. Cummings SR, San Martin J, McClung MR, et al. Deno-sumab for prevention of fractures in postmenopausal women with osteoporosis. N Engl J Med 2009 Aug; 361 (8): 756-65.
27. Reid I, Miller P, Brown J, et al., on behalf of the Denosumab Phase 3 Bone Histology Study Group. Effects of denosu-mab on bone histomorphometry: the freedom and stand studies. J Bone Miner Res 2010 Oct; 25 (10): 2256-65.
28. Riggs BL, Hartmann LC. Selective estrogen-receptor mod-ulators: mechanisms of action and application to clinical practice. N Engl J Med 2003 Feb; 348 (7): 618-29.
29. Neer RM, Arnaud CD, Zanchetta JR, et al. Effect of para-thyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. N Engl J Med 2001 May; 344 (19): 1434-41.
30. Whitfield JF, Morley P, Willick GE. Parathyroid hormone, its fragments and their analogs for the treatment of osteoporosis. Treat Endocrinol 2002; 1 (3): 175-90.
31. Reeve J. Recombinant human parathyroid hormone. BMJ 2002 May; 324 (7347): 435-6.
32. Marie PJ. Strontium ranelate: a dual mode of action re-balancing bone turnover in favour of bone formation. Curr Opin Rheumatol 2006 Jun; 18 Suppl. 1: S11-5.
33. Reginster JY, Deroisy R, Neuprez A, et al. Strontium ra-nelate: new data on fracture prevention and mechanisms of action. Curr Osteoporos Rep 2009 Sep; 7 (3): 96-102.
34. Deeks ED, Dhillon S. Strontium ranelate: a review of its use in the treatment of postmenopausal osteoporosis. Drugs 2010 Apr; 70 (6): 733-59.
35. Song F, Loke YK, Walsh T, et al. Methodological problems in the use of indirect comparisons for evaluating healthcare interventions: survey of published systematic reviews. BMJ 2009 Apr; 338: b1147.
36. Black DM, Cummings SR, Karpf DB, et al. Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures: Fracture Intervention Trial Research Group. Lancet 1996 Dec; 348 (9041): 1535-41.
37. Chesnut III CH, Skag A, Christiansen C, et al. Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 2004 Aug; 19 (8): 1241-9.
38. Harris ST, Watts NB, Genant HK, et al. Effects of rise-dronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group. JAMA 1999 Oct; 282 (14): 1344-52.
39. Reginster J, Minne HW, Sorensen OH, et al. Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Osteoporos Int 2000; 11 (1): 83-91.
40. Black DM, Delmas PD, Eastell R, et al. Once-yearly zole-dronic acid for treatment of postmenopausal osteoporosis. N Engl J Med 2007 May; 356 (18): 1809-22.
41. Ettinger B, Black DM, Mitlak BH, et al. Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. JAMA 1999 Aug; 282 (7): 637-45.
42. Cummings SR, Ensrud K, Delmas PD, et al. Lasofoxifene in postmenopausal women with osteoporosis. N Engl J Med 2010 Feb; 362 (8): 686-96.
43. Silverman SL, Christiansen C, Genant HK, et al. Efficacy of bazedoxifene in reducing new vertebral fracture risk in postmenopausal women with osteoporosis: results from a 3-year, randomized, placebo-, and active-controlled clinical trial. J Bone Miner Res 2008 Dec; 23 (12): 1923-34.
44. Meunier PJ, Roux C, Seeman E, et al. The effects of stron-tium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis. N Engl J Med 2004 Jan; 350 (5): 459-68.
45. McClung MR, Geusens P, Miller PD, et al. Effect of rise-dronate on the risk of hip fracture in elderly women: Hip Intervention Program Study Group. N Engl J Med 2001 Feb; 344 (5): 333-40.
46. Reginster JY, Seeman E, De Vernejoul MC, et al. Strontium ranelate reduces the risk of nonvertebral fractures in post-menopausal women with osteoporosis: TROPOS study. J Clin Endocrinol Metab 2005 May; 90 (5): 2816-22.
47. MacLaughlin EJ, Raehl CL. ASHP therapeutic position statement on the prevention and treatment of osteoporosis in adults. Am J Health Syst Pharm 2008 Sep; 65 (3): 343-57.
48. Sackett DL, Straus SE, Richardson WS, et al., editors. Evi-dence-based medicine: how to practice and teach EBM. 2nd ed. Edinburgh: Churchill Livingstone, 2001.
49. Moher D, Hopewell S, Schulz KF, et al. CONSORT 2010 explanation and elaboration: updated guidelines for reporting parallel group randomised trials. BMJ 2010 Mar; 340: c869.
50. Schulz KF, Altman DG, Moher D, CONSORT Group. CONSORT 2010 statement: updated guidelines for reporting parallel group randomised trials. BMJ 2010 Mar; 340: c332.
51. Gallagher JC, Genant HK, Crans GG, et al. Teriparatide reduces the fracture risk associated with increasing number and severity of osteoporotic fractures. J Clin Endocrinol Metab 2005 Mar; 90 (3): 1583-7.
52. Agence française de securite sanitaire des produits de sante. Traitement medicamenteux de l' osteoporose post-meno-pausique, 2006 [online]. Available from URL: http://www. afssaps.fr/Infos-de-securite/Recommandations-de- bonne-pratique/Traitement-medicamenteux-de-l-osteoporose-post-menopausique- recommandations-de-bonne-pratique/(lan guage)/fre-FR [Accessed 2010 Sep 1].
53. Committee for Medicinal Products for Human Use (CHMP). Guideline on the evaluation of medicinal products in the treatment of primary osteoporosis. Ref CPMP/EWP/552/95Rev.2. London: CHMP, 2006.
54. Kanis JA, McCloskey EV, Johansson H, et al. Development and use of FRAX in osteoporosis. Osteoporos Int 2010 Jun; 21 Suppl. 2: S407-13.
55. Kanis JA, Johnell O, Oden A, et al. FRAX and the assess-ment of fracture probability in men and women from the UK. Osteoporos Int 2008 Apr; 19 (4): 385-97.
56. Abrahamsen B. Adverse effects of bisphosphonates. Calcif Tissue Int 2010 Jun; 86 (6): 421-35.
57. Musette P, Brandi ML, Cacoub P, et al. Treatment of osteoporosis: recognizing and managing cutaneous adverse reactions and drug-induced hypersensitivity. Osteoporos Int 2010 May; 21 (5): 723-32.
58. Brennan TC, Rizzoli R, Ammann P. Selective modification of bone quality by PTH, pamidronate or raloxifene. J Bone Miner Res 2009 May; 24 (5): 800-8.
59. Allen MR. Surface-specific bone formation effects of osteoporosis pharmacological treatments. Clin Rev Bone Miner Metab 2008; 6 (1-2): 62-9.
60. Benhamou CL. Effects of osteoporosis medications on bone quality. Joint Bone Spine 2007 Jan; 74 (1): 39-47.
61. Meunier PJ, Boivin G, Marie PJ. About the comparison of two anabolic agents, teriparatide and strontium ranelate, in treated osteoporotic women [letter]. J Bone Miner Res 2009 Dec; 24 (12): 2066.
62. Rizzoli R, Laroche M, Krieg MA, et al. Strontium ranelate and alendronate have differing effects on distal tibia bone microstructure in women with osteoporosis. Rheumatol Int 2010 Aug; 30 (10): 1341-863.
63. Roux S. New treatment targets in osteoporosis. Joint Bone Spine 2010 May; 77 (3): 222-8